Jubilant Generics Limited

Ratiopharm Gmbh

Ganesh Vinayak Gat

Dinesh Kumar

Kamal Surendrakumar Mehta

Ravikumar Nithiyanandam

Premchand Dalichandji Nakhat

Saurabh Srivastava

Amit Jha

Javed Hussain

Subash Chandra Mohanta

Sunil Kumar Panda

Pankaj Soni

Indranil Nandi

Sandra Brueck

Julia Schulze Nahrup

Goutam Muhuri

Swati Mukherjee

Priyank Sharma

Bharat Bhushan

Baibhav Joshi

Pasupuleti Giridhara Rao

Anil Jain

Yogesh S Deshpande

Birgit Schnitter

Parshwakumar V Kalyankar

Jawed Hussain

Vivek Jain

Vikas Bali

Rashmi Ranjan Panda

Balamurugan Jeganathan

Sunil R Mhase

Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.

Transmucosal dosage forms of remdesivir

The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Delayed release pharmaceutical composition of pantoprazole and process for formulation thereof

The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.

Solid oral dosage forms of eslicarbazepine

The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Immediate release pharmaceutical composition of iron chelating agents

The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX&#xae; capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.

Immediate release pharmaceutical composition of tizanidine

The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

The present invention relates to pharmaceutical composition of Cinacalcet or a pharmaceutically acceptable salt thereof comprising diluents, binders and lubricants, wherein said composition is substantially free of disintegrant. It further relates to process for preparing such compositions.

Disintegrant free composition of Cinacalcet

The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 &#x3bc;m to 35 &#x3bc;m and d(0.5) of 3 &#x3bc;m to 20 &#x3bc;m, as well as methods for preparing said formulations.

Pharmaceutical formulation comprising ezetimibe

The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20&#xb0; C. to approx. 45&#xb0; C.

Process for the preparation of a medicament comprising vardenafil hydrochloride trihydrate

The present invention relates to Escitalopram having a small median particle size and a solid pharmaceutical composition comprising the same.

Escitalopram and solid pharmaceutical composition comprising the same

Growing community of inventors

Pune, India

Ganesh Vinayak Gat